Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-825 in Diffuse Cutaneous Systemic Sclerosis
2023-509782-20-00Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing HZN-825 with Placebo (2 arms). Primary endpoint: Forced vital capacity percent predicted. Started Jun 2024; status: completed.
02
Drugs
fipaxalparant
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on 2023-509782-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509782-20-00.